Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study is collecting real-world data to evaluate abrocitinib and conventional systemic treatments in moderate-to-severe atopic dermatitis across five European registers over a three-year period.

Poor air quality increases the risk of atopic dermatitis in Taiwan.

In this study, children with alopecia areata and comorbid atopic diseases experienced an earlier onset of the condition and were more likely to develop severe forms compared to those without atopy.

This study found that patients with alopecia areata have significantly higher medication adherence than those with atopic dermatitis, potentially due to the stability and controllability of alopecia areata symptoms.

In this study involving children with alopecia areata, researchers found that adding narrowband UVB 311 nm therapy to standard treatment significantly improved hair regrowth in those with coexisting atopic dermatitis compared to those without the condition.

This case report describes a patient with severe alopecia totalis and atopic dermatitis who showed almost complete hair regrowth and improved skin lesions after receiving subcutaneous allergen-specific immunotherapy using house dust mites.

This study found that fermented red ginseng marc alleviated atopic dermatitis-like symptoms in mice, demonstrating antioxidant and anti-inflammatory effects similar to those of dexamethasone.

This case report details a 46-year-old woman with severe atopic dermatitis and alopecia areata universalis who experienced renewed hair growth and improved skin symptoms after starting dupilumab therapy.

This study found that platelet-rich plasma treatment led to significant reductions in lesion sizes for both plaque psoriasis and atopic dermatitis, with many patients achieving complete remission and no adverse events reported.

Hospitalizations for atopic dermatitis are more due to other health issues now, not the condition itself.

This study found that skin-infiltrating neutrophils play a crucial role in triggering chronic itch in atopic dermatitis by promoting skin hyperinnervation and enhanced expression of itch signaling molecules in a mouse model.

This study examined the safety and efficacy of dupilumab in adolescents with moderate-to-severe atopic dermatitis, finding that it was well tolerated and significantly improved symptoms over 52 weeks, with its safety profile similar to that in adults.

Sodium hypochlorite can effectively prevent and remove Staphylococcus aureus biofilms in atopic dermatitis at high enough concentrations.

Mineral levels in hair don't significantly affect the severity of atopic dermatitis in children.

This article discusses research about Netherton syndrome, highlighting its contributions to understanding epidermal structure, immune responses, and processes like atopic dermatitis, but it reports no new clinical findings.

In this case report, a 28-year-old male with severe atopic dermatitis, prurigo nodularis-like lesions, and alopecia areata showed rapid improvements in skin and hair following treatment with the JAK1 inhibitor, ivarmacitinib, suggesting its potential benefit for complex AD phenotypes with immune-mediated hair loss.

This review highlights advancements in drug delivery systems for treating psoriasis and atopic dermatitis, focusing on their ability to enhance transdermal drug efficacy and safety by overcoming skin barriers and enabling precise, on-demand drug release at target sites.

In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.

This review discusses the role of JAK inhibitors in treating atopic dermatitis, alopecia areata, and vitiligo, highlighting their effectiveness and safety considerations but stressing the need for further research on long-term safety and patient selection.

This review discusses the dual role of extracellular vesicles in the pathophysiology and treatment of atopic dermatitis but reports no new clinical results; future research should address standardization and safety challenges.

In this study, researchers observed that atopic dermatitis may alter the appearance of allergic patch test reactions, demonstrating specific patterns like perifollicular erythema and yellowish areas that could aid in interpreting patch tests using dermoscopy, particularly in ambiguous cases.

This review discusses recent advancements in nanotechnology for treating hypertrophic scarring and atopic dermatitis, highlighting the potential of nanotherapeutic platforms in enhancing therapeutic effects by modulating the skin's microenvironment.

This narrative review highlights the shared immunopathogenesis of alopecia areata and atopic dermatitis and discusses approved and investigational therapies that target common pathways, suggesting a future for personalized treatment strategies.

This clinical study found that using a cream or lotion as an additional treatment alongside standard care for atopic dermatitis significantly reduced symptoms and improved skin moisturization and barrier function within 28 days compared to standard care alone in participants with mild-to-moderate eczema.

In this study, dogs with atopic dermatitis showed significant improvements in macroscopic skin lesions, such as reduced pruritus and hair regrowth, after receiving coconut oil massages every three days for 33 days.

In this study, researchers created a detailed human skin cell atlas by analyzing over 700,000 cells, finding that disrupted communication among specific immune and stromal cell subsets may play a key role in initiating and sustaining chronic skin inflammation in atopic dermatitis.

In this study analyzing FDA data, researchers found that tralokinumab was associated with higher reports of conjunctivitis and keratitis compared to dupilumab, while dupilumab had more frequent injection site reactions, highlighting potential risks for clinical monitoring in atopic dermatitis treatments.

This study found that intradermal injections of Profhilo® significantly reduced skin inflammation and pain, while altering spinal cord markers in mice with ovalbumin-induced atopic dermatitis, suggesting potential therapeutic benefits for inflammatory skin conditions involving both peripheral and central processes.

In a DNFB-induced mouse model of atopic dermatitis, this study found that both topical and oral formulations of the probiotic Bifidobacterium animalis J12 improved AD symptoms through distinct mechanisms, with topical applications reducing local inflammation and oral administration enhancing gut microbiota and reducing systemic inflammation.

In this study, researchers used a mouse model to identify an adipocyte-to-fibroblast conversion pathway that promotes mast-cell recruitment and dermal fibrosis in atopic dermatitis, suggesting a potential therapeutic approach to block this process and reduce inflammation and fibrosis.